| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | NEUTRAL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 7.03▼ | 7.02▼ | 6.95▼ | 6.86▲ | 7.01▼ |
| MA10 | 7.09▼ | 6.82▲ | 6.77▲ | 6.98▼ | 7.73▼ |
| MA20 | 6.95▼ | 6.75▲ | 6.81▲ | 7.02▼ | 8.59▼ |
| MA50 | 6.83▲ | 6.84▲ | 6.89▼ | 8.01▼ | 8.12▼ |
| MA100 | 6.87▼ | 6.97▼ | 7.06▼ | 8.65▼ | 13.09▼ |
| MA200 | 7.00▼ | 7.46▼ | 7.82▼ | 8.60▼ | 19.72▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.011▼ | 0.051▲ | 0.039▲ | 0.059▲ | -0.214▼ |
| RSI | 47.587▼ | 51.736▲ | 51.239▲ | 45.376▼ | 41.216▼ |
| STOCH | 39.050 | 79.663 | 68.361 | 49.224 | 12.022▼ |
| WILL %R | -94.624▼ | -48.889 | -48.889 | -40.945 | -89.945▼ |
| CCI | -85.906 | 50.699 | 57.980 | -0.019 | -87.631 |
|
Thursday, March 05, 2026 03:03 AM
Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for ...
|
|
Thursday, February 26, 2026 05:22 AM
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ...
|
|
Monday, February 23, 2026 06:33 AM
The presentations can be found on the Posters & Presentations section of the Aligos website ( www.aligos.com) after the live event.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 06/03/26 | 6.40 | 7.37 | 6.365 | 6.98 | 87,271 |
| 05/03/26 | 6.80 | 7.01 | 6.3795 | 6.66 | 31,864 |
| 04/03/26 | 6.75 | 7.165 | 6.73 | 6.86 | 41,439 |
| 03/03/26 | 6.75 | 6.92 | 6.50 | 6.85 | 31,127 |
| 02/03/26 | 6.88 | 7.075 | 6.31 | 6.965 | 94,937 |
| 27/02/26 | 7.36 | 7.383 | 6.95 | 7.03 | 21,963 |
| 26/02/26 | 6.99 | 7.50 | 6.905 | 7.50 | 25,397 |
| 25/02/26 | 7.06 | 7.10 | 6.73 | 6.94 | 34,079 |
| 24/02/26 | 7.00 | 7.25 | 6.85 | 7.09 | 20,085 |
| 23/02/26 | 6.85 | 7.1899 | 6.58 | 6.94 | 0 |
|
|
||||
|
|
||||
|
|